FDA 483 - Pfizer Manufacturing Belgium NV - June 08, 2023

An FDA inspection conducted at Pfizer Manufacturing Belgium NV, located in Puurs-Sint-Amands, Antwerp, Belgium, from June 5 to June 8, 2023, resulted in a Form FDA 483 observation. The primary issue identified was the inadequate documentation of corrective and preventive action (CAPA) activities and their results. Specifically, the inspection highlighted deficiencies in the documentation of investigations related to CAPA 6586513, which was initiated to address trends concerning injector pen devices, particularly complaints involving blockages and underfill issues. The FDA noted that not all activities for these investigations were adequately recorded, indicating a lapse in the firm's quality system procedures for addressing product defects. This observation falls under the regulatory framework of the Federal Food, Drug, and Cosmetic Act, which mandates proper controls for manufacturing establishments. While the FDA 483 itself is an observation and not a final determination of compliance, it signals areas requiring immediate attention. Pfizer Manufacturing Belgium NV is responsible for conducting thorough internal self-audits to identify and rectify all violations of quality system requirements. The firm has promised to correct the identified observation by December 8, 2023, underscoring the need for improved documentation and robust CAPA processes to ensure product quality and patient safety.